Skip to content

One-step HCV RNA Testing Among SSP Participants (HOT Study)

Clinical Utility and Feasibility of a One-step HCV Testing Algorithm for Clients of a U.S. Syringe Services Program

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06634342
Acronym
HOT
Enrollment
200
Registered
2024-10-09
Start date
2025-02-05
Completion date
2026-04-30
Last updated
2026-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Testing Effect of Intervention

Brief summary

The HOT (HCV One-step Test) Study is an observational prospective study to evaluate the use of a recently FDA-approved point-of-care RNA test for hepatitis C virus (HCV) in a sample of clients of a syringe services program (SSP). The investigators aim to answer the following questions: 1\. How will point-of-care HCV RNA testing with the Xpert HCV test, provided at an SSP, affect how people who use drugs receive their results, get linked to HCV care services, and initiate and complete HCV treatment? 2: What are the most effective ways to implement point of care HCV RNA testing in syringe services programs?

Detailed description

This study will be conducted in partnership with the Public Health - Seattle & King County SSP in Seattle WA. The PHSKC SSP will be provided with a Cepheid Xpert HCV RNA machine and testing cartridges. Staff will be trained by Cepheid staff on the one-step HCV RNA testing protocol, including collecting blood from participants, using the test machine, interpreting results, and returning results to participants. HCV testing and linkage to care activities will be monitored for six months as part of this study. Once all training and protocol development is complete, the PHSKC SSP will make the one-step HCV testing algorithm available to their clients and invite them to participate. SSP staff will conduct the one-step HCV testing and linkage algorithm according to the project protocol. Clients who choose to be tested will participate in an informed consent process for study procedures. Participants who complete the HCV test and receive their results will receive a $15 incentive. All quantitative data related to the study will be entered directly into REDCap data collection tools. SSP staff who conduct testing will record a participant's HCV test result, whether/when they received their result, and whether/when they received a referral to HCV care. Participants will need to provide identifying information (e.g., name and birthdate) and sign a release of information form to facilitate longitudinal data collection on linkage to care and treatment initiation. SSP staff will use this information to follow up with providers to indicate whether/when participants attended an HCV care visit, whether/when participants began HCV treatment, and if they achieved cure (i.e., sustained viral response at 4 weeks). No other information will be requested or recorded from health care providers. Investigators will ask the PHSKC SSP to gather data on prior HCV testing and linkage efforts for the 6 months prior to the implementation of the one-step algorithm (standard of care). This will include any data that are available related to volume of HCV screening and RNA testing, participant receipt of results, and linkage to care efforts. During the six months of the testing project, investigators will also conduct qualitative data collection. First, UW staff will conduct 12 in-depth interviews with participants who were involved in the testing component of the study. These interviews will be conducted with participants who received negative HCV RNA results, both those who were and were not linked to care, and those who started HCV treatment. The goal of these interviews will be to understand the participants' previous testing experiences and interest in HCV care, present testing experiences and interest in care, and overall impressions of the one-step testing algorithm. Staff will use purposive sampling to recruit participants and conduct private interviews using a semi-structured interview guide. Participants who complete these interviews will receive a $40 incentive. Second, UW staff will conduct in-depth interviews with all staff at the PHSKC SSP who were involved with the HCV testing study to understand the experiences of staff who conducted the one-step testing algorithm compared to previous testing algorithms (e.g., HCV rapid screening and/or laboratory-based HCV RNA testing). Specific questions will assess facilitators and barriers to providing one-step HCV testing in SSPs, as well as recommendations for implementing similar protocols in other SSPs.

Interventions

DIAGNOSTIC_TESTHCV RNA Rapid testing

Participants will receive point-of-care hepatitis C RNA testing using the GeneXpert IV Xpress System technology.

Sponsors

University of Washington
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Minimum age of 22

Exclusion criteria

* Already knows they are infected with hepatitis C virus. * Past participation in this study.

Design outcomes

Primary

MeasureTime frameDescription
Receipt of HCV RNA Test Results6 monthsPercentage of individuals who complete a HCV RNA test and who also receive their test results.
Linkage to HCV Care6 monthsPercentage of individuals who test positive for HCV who are connected with HCV treatment services
Cure Rate6 monthsPercentage of individuals who test positive for HCV who are cured of HCV.

Secondary

MeasureTime frameDescription
Testing Results6 monthsPercentage of participants who receive an HCV RNA test who test positive for HCV
Testing Willingness6 monthsPercentage of participants offered the HCV RNA test who agree to be tested

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORSara Glick, PhD, MPH

University of Washington

Baseline characteristics

Characteristic
Age, Customized
22-29 years
24 Participants
Age, Customized
30-39 years
73 Participants
Age, Customized
40-49 years
51 Participants
Age, Customized
50-59 years
37 Participants
Age, Customized
60+ years
15 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
34 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
159 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
7 Participants
History of injection drug use, ever
No
51 Participants
History of injection drug use, ever
Yes
149 Participants
Race (NIH/OMB)
American Indian or Alaska Native
15 Participants
Race (NIH/OMB)
Asian
3 Participants
Race (NIH/OMB)
Black or African American
37 Participants
Race (NIH/OMB)
More than one race
12 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
21 Participants
Race (NIH/OMB)
White
112 Participants
Sex/Gender, Customized
Female
64 Participants
Sex/Gender, Customized
Male
129 Participants
Sex/Gender, Customized
Non-binary
2 Participants
Sex/Gender, Customized
Other/no response
4 Participants
Sex/Gender, Customized
Trans female
1 Participants
Sex/Gender, Customized
Trans male
0 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 200
other
Total, other adverse events
0 / 200
serious
Total, serious adverse events
0 / 200

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 14, 2026